Clinical BeiGene Brukinsa ready to compete with J&J’s Imbruvika

BeiGene Brukinsa ready to compete with J&J’s Imbruvika


BeiGene is prepared for their leukemia disease cure, Brukinsa, to clash with J&J (Johnson & Johnson) and AbbVie’s Imbruvica. The company claims that it has medical evidence stating that its cure has shown the ability to treat rare blood-related malignancies.

As per a statement released by BeiGene, Brukinsa performed better than J&J’s Imbruvica in reducing the death rate and treating chronic leukemia or small lymphoma.

The accuracy of the research is dependent on the ALPINE analysis phase 3 trial. Brukinsa was approved by two sets of benches, namely the independent review committee and an individual investigator, as per BeiGene.

During the ALPINE interim analysis trial, which took place last year, Brukinsa won the race in the chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) trials, showing a noticeable increase in tumor shrinkage. This was the main aim of the company and a setback for Imbruvica.

The statistics of the research were shared at the remote European Hematology Association 2021, although BeiGene did not provide detailed results in their statements. Brukinsa tumor shrinkage results were seen in 78% of the patients compared to Imbruvica whose results were roughly 63%. One thing to be looked upon is that at the time of the study it was anticipated that 94.9% of Brukinsa participants would be alive without illness advancement after one year, compared to 84% in the case of Imbruvica, leading to a 59.8% decrease in risk.

ALPINE is the second study taking place between Brukinsa and Imbruvica, but this time BeiGene has their product ready to compete in a market in which Imbruvica has the majority market share. Brukinsa was previously defeated by Imburvica in tumor reduction at the ASPEN phase 3 study.

BeiGene has submitted a new FDA application that combines ALPINE and results from the phase 3 SEQUOIA study in newly diagnosed CLL/SLL, but not head-to-head against Imbruvica. The application has a target action date of January 20, 2023, extended by three months when BeiGene submitted new tumor response data from ALPINE.

Brukinsa has already been successful in capturing market share and along with Calquence (Astrazeneca medication for cardiac) is giving Imbruvica a competition. The sales of the monopoly maker reduced by 4% and 7.4% in the first and second quarters to $1.04 billion and close to $30 million short of a billion.

The situation in the case of BeiGene has been highly positive with Brukinsa’s sales increasing by 23% in the second quarter reaching an all-time high figure of a million short of $130 million.

Andrew Berens, an Analyst at SVB securities released a statement”

“Burkinsa has been successful in pulling new patient groups which is a major reason for their increase in sales but have been partially unsuccessful in converting Imbruvica’s consumer base. AstraZeneca’s product has a higher rate of converting Imbruvica patients”.

Latest news

Life Sciences Voice Top Five Newsletter

Welcome to the latest edition of the Life Sciences Voice Top Five Newsletter, your source for the top developments...

Pfizer’s Phase 3 Trial for Gene Therapy in Boys with Duchenne Muscular Dystrophy Fails to Show Functional Improvement

Pfizer's gene therapy for Duchenne muscular dystrophy failed to improve motor function in young boys in a key late-stage...

Phase 3 Trial Results for Loqtorzi Show Positive Results in Advanced Hepatocellular Carcinoma Patients

Phase 3 trial results for Loqtorzi (toripalimab) and Avastin (bevacizumab) show that in first-line patients suffering from advanced hepatocellular...

Must read

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm

You might also likeRELATED
Recommended to you